DUBLIN--(BUSINESS WIRE)--Aug 22, 2018--The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the report:

The report provides a snapshot of the pipeline development for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The report also covers the dormant and discontinued pipeline projects related to the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Key Topics Covered:

1. Report Introduction

2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

4. Comparative Analysis

5. Products in Clinical Stage

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

Product Description Research and Development Product Development Activities

Companies Mentioned

MedDay Pharmaceuticals SA Baxalta US Inc. Laboratoire franais de Fractionnement et de Biotechnologies Octapharma Baxter International LFB Biotechnologies

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zn7hh9/chronic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180822005603/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/22/2018 02:25 PM/DISC: 08/22/2018 02:25 PM

http://www.businesswire.com/news/home/20180822005603/en